EP Patent

EP0344383A1 — Novel alpha-Glucosidase inhibitors

Assigned to Aventis Pharmaceuticals Inc · Expires 1989-12-06 · 36y expired

What this patent protects

This invention relates to novel N-derivatives of 1-deoxy-nojirimyoin, to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes.

USPTO Abstract

This invention relates to novel N-derivatives of 1-deoxy-nojirimyoin, to the processes for their preparation and to their end-use applications, particularly as to their use in the treatment of diabetes.

Drugs covered by this patent

Patent Metadata

Patent number
EP0344383A1
Jurisdiction
EP
Classification
Expires
1989-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.